<DOC>
	<DOCNO>NCT00393445</DOCNO>
	<brief_summary>The purpose study determine dose GLP-1 receptor antagonist exendin ( 9-39 ) block insulinotropic action synthetic GLP-1 least 95 % .</brief_summary>
	<brief_title>Exendin ( 9-39 ) Amide Glucagon-like Peptide-1 ( GLP-1 ) Receptor Antagonist Humans</brief_title>
	<detailed_description>Following meal , gut-produced incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) release circulation . GLP-1 GIP , two dominant incretin hormone , part natural endogenous system involve maintain glucose homeostasis . In presence normal elevate , low , glucose concentration , GLP-1 GIP increase insulin secretion pancreatic islet beta-cells ( β-cells ) . GLP-1 also lower glucagon secretion pancreatic alpha-cells delay nutrient delivery stomach inhibit gastric emptying . This rise insulin concentration enhances glucose clearance peripheral tissue muscle , low glucagon concentration combine rise insulin reduces hepatic glucose production . By enhance glucose clearance lower hepatic glucose production , post-meal glucose excursion reduce . However , role incretin glucoregulation fully understood . Use GLP-1 antagonist , exendin ( 9-39 ) NH2 , allow assessment non-GLP-1 incretin 's role glucoregulation . Therefore , great interest examine role specific incretins glucoregulation patient T2DM . Exendin ( 9-39 ) show specific reversible antagonist human GLP-1 receptor vivo . In initial validation study intravenous exendin ( 9-39 ) dose-dependently reduce insulinotropic action intravenous GLP-1 . The maximal dose 300 pmol/kg/min use study sufficient reduce GLP-1 stimulated insulin plasma level 83 % . However , quantify contribution incretin hormone incretin effect state nearly complete inhibition GLP-1 action necessary . Therefore purpose pilot study characterize dose-response characteristic exendin ( 9-39 ) completely find dosage inhibits insulinotropic action GLP-1 least 95 % .</detailed_description>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Male female ( postmenopausal , surgically sterile use doublebarrier method contraception ) healthy volunteer Age 1865 year Hemoglobin A1c ( HbA1c ) &lt; 6 % Body mass index ( BMI ) &lt; 30 kg/m2 Must fast blood glucose 100 mg/dl screen study day Able provide write informed consent prior study participation Able communicate well investigator comply requirement study Diabetes mellitus Fasting triglyceride &gt; 5.1 mmol/L ( &gt; 450 mg/dL ) within past 4 week . Treatment systemic steroid thyroid hormone Patients history gastrointestinal surgery , e.g . partial bowel resection , partial gastric resection , etc . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Past medical history clinically significant electrocardiogram ( ECG ) abnormalities family history prolong QTinterval syndrome . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study . The investigator guide evidence following : history inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleed history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection history clinical evidence pancreatic injury pancreatitis history presence impair renal function indicate abnormal creatinine urea value abnormal urinary constituent ( e.g. , albuminuria ) evidence urinary obstruction difficulty void screen Polymorphonuclears &lt; 1500/µL inclusion platelet count &lt; 100,000/μL screen baseline . Evidence liver disease indicate abnormal liver function test SGOT , SGPT , GGT , alkaline phosphatase , serum bilirubin . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Exendin ( 9-39 )</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Human physiology</keyword>
</DOC>